Lv61
2060 积分 2023-03-20 加入
Deciphering Binding Interactions of IL-23R with HDX-MS: Mapping Protein and Macrocyclic Dodecapeptide Ligands
2天前
已完结
Oral IL-23-blocking peptide racks up phase III wins in inflammatory disease
2天前
已完结
Species Differences in Size Discrimination in the Paracellular Pathway Reflected by Oral Bioavailability of Poly(ethylene glycol) and d-Peptides
2天前
已完结
The novel lysophosphatidic acid receptor 1-selective antagonist, ACT-1016-0707, has unique binding properties that translate into effective anti-fibrotic and anti-inflammatory activity in different models of pulmonary fibrosis
3天前
已完结
Lysophosphatidic Acid Receptor Agonism: Discovery of Potent Nonlipid Benzofuran Ethanolamine Structures
3天前
已完结
The novel lysophosphatidic acid receptor 1-selective antagonist, ACT-1016-0707, has unique binding properties that translate into effective anti-fibrotic and anti-inflammatory activity in different models of pulmonary fibrosis
3天前
已完结
Current role of pasireotide in the treatment of acromegaly
8天前
已完结
Trends in the drug target landscape for autoimmune diseases
8天前
已完结
Tumour-derived small extracellular vesicles act as a barrier to therapeutic nanoparticle delivery
8天前
已完结
Insulin resistance in type 2 diabetes mellitus
10天前
已完结
皖公网安备34019202002308
